AFYMOD

Welcome to the Brand page for “AFYMOD”, which is offered here for (based on 44(d) priority application) vaccines; pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(based on 44(e)) vaccines; pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders;.

Its status is currently believed to be active. Its class is unavailable. “AFYMOD” is believed to be currently owned by “GLAXO GROUP LIMITED”.